Treating HIV/AIDS and leishmaniasis coinfection in Ethiopia

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 11, 2005, Pages 1434-1435

  Anema, Aranka ^a   Ritmeijer, Koert ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; STIBOGLUCONATE SODIUM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGRICULTURAL WORKER; CLIMATE CHANGE; COMORBIDITY; ETHIOPIA; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; LYMPHOCYTE COUNT; MASS SCREENING; OPPORTUNISTIC INFECTION; SEASONAL VARIATION; SEXUAL BEHAVIOR; SHORT SURVEY; VIRUS TRANSMISSION; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

EID: 20444413452     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.050511     Document Type: Short Survey

References (2)

1. Alvar J, Gutierrez-Solar B, Molina R, Lopez-Velez R, Garcia-Camacho A, Martinez P, et al. Prevalence of Leishmania infection among AIDS patients [letter]. Lancet 1992;339:1427.
2. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients, have a poor outcome. Trans R Soc Trop Med Hyg 2001;95:668-72.